Single Blog

Why Gefapixant Is a Breakthrough for Chronic Cough

Chronic cough lasting longer than eight weeks is more than an annoying symptom; it can dominate daily life, disrupt sleep, strain relationships, and fuel anxiety and depression. For many adults, cough persists despite optimal management of asthma, GERD, or upper airway cough syndrome, leading to a diagnosis of refractory or unexplained chronic cough.

Until recently, clinicians relied on off-label neuromodulators such as gabapentin, amitriptyline, or even low-dose opioids. These options carry sedation, cognitive impairment, and dependence risks, and often provide incomplete relief. Gefapixant, a first-in-class P2X3 receptor antagonist, is poised to change this landscape by targeting the biology of cough hypersensitivity rather than merely dulling the central nervous system.

What Is Gefapixant and How Does It Work?

Gefapixant is an oral small-molecule antagonist of the P2X3 receptor, a subtype of ATP-gated ion channels located on vagal sensory neurons in the airways. In chronic cough, these neurons become hypersensitive, so minor stimuli—such as cold air, talking, or light odors—can trigger intense and frequent coughing.

When airway nerves are irritated, they release ATP, which binds to P2X3 receptors and activates the cough reflex. Gefapixant binds to these receptors and prevents ATP from triggering them, effectively “turning down” the overactive cough circuit while preserving protective cough mediated by other pathways. Early mechanistic work demonstrated that gefapixant reduces cough reflex sensitivity and objective cough counts in a dose-dependent fashion, supporting this targeted mode of action (doi:10.1016/S2213-2600(19)30367-0).

Clinical Evidence: Does Gefapixant Really Help Patients?

Phase 2 Proof of Concept

In a pivotal phase 2b trial in adults with refractory chronic cough, gefapixant significantly reduced 24-hour cough frequency compared with placebo. Patients also reported improvements in cough severity and cough-related quality of life, confirming that objective benefits translated into meaningful symptom relief (doi:10.1016/S2213-2600(19)30367-0).

Phase 3 COUGH-1 and COUGH-2 Trials

Two large phase 3 studies, COUGH-1 and COUGH-2, evaluated gefapixant 45 mg twice daily in patients with refractory or unexplained chronic cough. Key findings included:

• Significant reduction in 24-hour cough frequency versus placebo.
• Rapid onset of effect within weeks, sustained over long-term follow-up.
• Consistent efficacy across multiple patient subgroups, suggesting broad applicability.

Crucially, patient-reported outcomes—such as cough severity scores and health-related quality of life—also improved, underscoring the real-world impact of therapy (doi:10.1056/NEJMoa2108569).

Safety Profile: The Taste Trade-Off

The primary safety signal with gefapixant is taste disturbance, including dysgeusia (altered taste), ageusia (loss of taste), and hypogeusia (reduced taste). These effects are thought to arise from P2X3 and related P2X2/3 receptor blockade in taste buds.

• Taste-related adverse events are dose-dependent and more frequent at higher doses.
• Most events are mild to moderate and reversible after dose reduction or discontinuation.
• Some patients discontinue therapy due to taste changes, yet many continue, reflecting the heavy burden of chronic cough and the value they place on cough relief.

Compared with centrally acting antitussives and off-label neuromodulators, gefapixant shows a favorable profile regarding sedation, cognitive side effects, and abuse potential (doi:10.1016/S2213-2600(19)30367-0; doi:10.1056/NEJMoa2108569).

What Gefapixant Means for the Future of Cough Medicine

Gefapixant is more than a single new drug; it validates a precision-medicine approach to chronic cough. By proving that selectively targeting P2X3 receptors can meaningfully reduce cough frequency, it opens several new avenues:

• Development of next-generation P2X3 antagonists with fewer taste-related side effects.
• Rational combination strategies with other neuromodulators or anti-inflammatory agents.
• Broader exploration of ATP-gated receptors in respiratory, pain, and sensory disorders.

For clinicians, gefapixant represents the move from empirical, trial-and-error prescribing to mechanism-driven therapy in chronic refractory cough. For patients, it offers a realistic prospect of regaining control over a symptom that has often dominated their lives.

Key References

• Dicpinigaitis PV, Morice AH, Birring SS, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory chronic cough: a randomized, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020;8(8):775–785. doi:10.1016/S2213-2600(19)30367-0
• McGarvey L, Birring SS, Morice AH, et al. Two randomized trials of gefapixant for refractory or unexplained chronic cough. N Engl J Med. 2022;386(10):941–953. doi:10.1056/NEJMoa2108569